Venus Concept Raises a Total of Approximately $2.7 Million in Gross Proceeds from Previously Announced Registered Direct Offerings of Common Stock
Venus Concept (NASDAQ: VERO) has successfully completed its previously announced registered direct offerings, raising total gross proceeds of approximately $2.7 million. The latest offering closed with the sale of 386,700 shares of common stock at $4.06 per share, generating approximately $1.57 million. This follows a previous offering that closed on April 10, 2025, which raised approximately $1.15 million.
The offerings were conducted as registered direct offerings priced at-the-market under Nasdaq rules, with H.C. Wainwright & Co. serving as the exclusive placement agent. The medical aesthetic technology company plans to use the net proceeds for general corporate purposes. The shares were offered through a shelf registration statement on Form S-3 that was declared effective by the SEC on November 1, 2024.
Venus Concept (NASDAQ: VERO) ha completato con successo le sue offerte dirette registrate precedentemente annunciate, raccogliendo un totale di proventi lordi di circa 2,7 milioni di dollari. L'ultima offerta si è chiusa con la vendita di 386.700 azioni ordinarie a 4,06 dollari per azione, generando circa 1,57 milioni di dollari. Questo segue una precedente offerta chiusa il 10 aprile 2025, che aveva raccolto circa 1,15 milioni di dollari.
Le offerte sono state condotte come offerte dirette registrate a prezzo di mercato secondo le regole Nasdaq, con H.C. Wainwright & Co. come agente di collocamento esclusivo. L'azienda specializzata in tecnologia estetica medica prevede di utilizzare i proventi netti per scopi aziendali generali. Le azioni sono state offerte tramite una dichiarazione di registrazione a scaffale sul modulo S-3, dichiarata efficace dalla SEC il 1° novembre 2024.
Venus Concept (NASDAQ: VERO) ha completado con éxito sus ofertas directas registradas previamente anunciadas, recaudando un total de ingresos brutos de aproximadamente 2,7 millones de dólares. La última oferta se cerró con la venta de 386,700 acciones ordinarias a 4,06 dólares por acción, generando aproximadamente 1,57 millones de dólares. Esto sigue a una oferta anterior que se cerró el 10 de abril de 2025, la cual recaudó aproximadamente 1,15 millones de dólares.
Las ofertas se realizaron como ofertas directas registradas a precio de mercado según las normas de Nasdaq, con H.C. Wainwright & Co. como agente de colocación exclusivo. La empresa de tecnología estética médica planea utilizar los ingresos netos para propósitos corporativos generales. Las acciones se ofrecieron mediante una declaración de registro en estante en el Formulario S-3, que fue declarada efectiva por la SEC el 1 de noviembre de 2024.
Venus Concept (NASDAQ: VERO)는 이전에 발표한 등록 직접 공모를 성공적으로 완료하여 총 약 270만 달러의 총 수익을 모금했습니다. 이번 공모는 보통주 386,700주를 주당 4.06달러에 판매하며 약 157만 달러를 창출했습니다. 이는 2025년 4월 10일에 마감된 이전 공모에서 약 115만 달러를 모금한 데 이은 것입니다.
이번 공모는 나스닥 규정에 따라 시가로 가격이 책정된 등록 직접 공모 방식으로 진행되었으며, H.C. Wainwright & Co.가 단독 배정 대행사로 참여했습니다. 의료 미용 기술 회사인 Venus Concept은 순수익을 일반 기업 목적에 사용할 계획입니다. 주식은 2024년 11월 1일 SEC가 효력을 인정한 Form S-3 선반 등록 명세서를 통해 제공되었습니다.
Venus Concept (NASDAQ : VERO) a réussi à finaliser ses offres directes enregistrées précédemment annoncées, levant un total de produits bruts d'environ 2,7 millions de dollars. La dernière offre s'est clôturée avec la vente de 386 700 actions ordinaires à 4,06 dollars par action, générant environ 1,57 million de dollars. Cela fait suite à une offre précédente clôturée le 10 avril 2025, qui avait levé environ 1,15 million de dollars.
Les offres ont été réalisées sous forme d'offres directes enregistrées à prix de marché selon les règles du Nasdaq, avec H.C. Wainwright & Co. en tant qu'agent de placement exclusif. La société spécialisée dans la technologie esthétique médicale prévoit d'utiliser les produits nets à des fins générales d'entreprise. Les actions ont été proposées via une déclaration d'enregistrement sur étagère, formulaire S-3, déclarée effective par la SEC le 1er novembre 2024.
Venus Concept (NASDAQ: VERO) hat seine zuvor angekündigten registrierten Direktplatzierungen erfolgreich abgeschlossen und dabei insgesamt Bruttoerlöse von etwa 2,7 Millionen US-Dollar erzielt. Das jüngste Angebot wurde mit dem Verkauf von 386.700 Stammaktien zu 4,06 US-Dollar je Aktie abgeschlossen und generierte rund 1,57 Millionen US-Dollar. Dies folgt auf ein vorheriges Angebot, das am 10. April 2025 geschlossen wurde und etwa 1,15 Millionen US-Dollar einbrachte.
Die Angebote wurden als registrierte Direktplatzierungen zum Marktpreis gemäß den Nasdaq-Regeln durchgeführt, wobei H.C. Wainwright & Co. als exklusiver Platzierungsagent fungierte. Das Unternehmen für medizinische Ästhetiktechnologie plant, die Nettoerlöse für allgemeine Unternehmenszwecke zu verwenden. Die Aktien wurden über eine Shelf-Registrierungserklärung auf Formular S-3 angeboten, die von der SEC am 1. November 2024 für wirksam erklärt wurde.
- Successfully raised $2.7 million in gross proceeds through two offerings
- Completed offerings through established SEC registration process
- Dilution of existing shareholders through new share issuance
- Relatively small capital raise may indicate funding options
- At-the-market offering typically indicates urgent capital needs
Insights
Venus Concept's registered direct offerings totaling
This capital raise is particularly notable given Venus Concept's market capitalization of approximately
The stated use of proceeds for "general corporate purposes" lacks specificity, which typically signals potential working capital needs rather than strategic growth initiatives. For medical aesthetic technology companies like Venus Concept, maintaining adequate operational funding is essential while navigating the competitive landscape.
While any additional capital provides financial flexibility, the pricing discount and the relative size of this offering compared to the company's market value suggest challenging financial circumstances. Investors should monitor upcoming financial disclosures for more clarity on cash position, burn rate, and operational trajectory to better assess whether this capital infusion will meaningfully strengthen Venus Concept's financial foundation.
TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 386,700 shares of common stock at a purchase price of
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
The gross proceeds to the Company from the offering were approximately
The shares of common stock described above were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-282811) that was declared effective by the Securities and Exchange Commission (the “SEC”) on November 1, 2024. The offering of the shares of common stock was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the registered direct offering was filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, New York 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Venus Concept
Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 12 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa Pro, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.
Forward-Looking Statements
This communication contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements about the Company’s financial condition, and other statements containing the words “expect,” “intend,” “may,” “will,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about the Company’s business and the industry in which it operates and management’s beliefs and assumptions and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond the Company’s control. Factors that could materially affect the Company’s business operations and financial performance and condition include, but are not limited to, the intended use of proceeds from the offering, those risks and uncertainties described under Part I Item 1A—“Risk Factors” in the Company’s most recent Annual Report on Form 10-K, Part II Item 1A—“Risk Factors” in the Company’s most recent Form 10-Q and in other documents the Company may file with the SEC. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to the Company as of the date hereof. Unless required by law, the Company does not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise.
Investor Relations Contact: ICR Westwicke on behalf of Venus Concept: Mike Piccinino, CFA VenusConceptIR@westwicke.com
FAQ
How much did Venus Concept (VERO) raise in their April 2025 stock offerings?
What was the share price for VERO's latest stock offering in April 2025?
How many shares did Venus Concept (VERO) sell in their latest offering?
What will Venus Concept use the proceeds from the April 2025 offerings for?
